Zomedica Enhances TRUFORMA® Platform With Launch of Advanced Canine Cortisol Assay

Zomedica Corp. (NYSE American:ZOM) has announced the launch of an improved canine cortisol assay for its TRUFORMA in-clinic biosensor testing platform. This assay, essential for many veterinary diagnostics, now offers better precision and accuracy. Zomedica initiated shipments earlier this month.

Ashley Wood, PhD, Vice President of Research and Development at Zomedica, stated that continual optimization based on field feedback has led to significant advancements. This assay is vital for crucial tests like the Low Dose Dexamethasone suppression test, delivering reference lab accuracy within veterinary clinics.

The TRUFORMA platform allows rapid in-house diagnostics, eliminating delays from external lab sample shipments. This innovation is projected to enhance patient care and operational efficiency, tapping into a $1.5 billion annual revenue opportunity in the US with its 14 assays.

T.J. Barclay, Zomedica Professional Services Veterinarian, emphasized the improved dynamic range of the assay by over 45%, enhancing the monitoring of cortisol levels post-treatment, crucial for managing conditions like Cushing's disease.